Alphatec (ATEC) 10-Q 1 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 29, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'ATEC	'
Entity Registrant Name	'Alphatec Holdings, Inc.	'
Entity Central Index Key	'0001350653	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	97,675,388

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash	$23,764	$21,345
Restricted cash	17,750	0
Accounts receivable, net	38,838	41,395
Inventories, net	42,542	41,939
Prepaid expenses and other current assets	11,168	7,694
Deferred income tax assets	1,388	1,372
Total current assets	135,450	113,745
Property and equipment, net	28,136	28,030
Goodwill	183,088	183,004
Intangibles, net	37,176	39,064
Other assets	2,432	1,787
Total assets	386,282	365,630
Current liabilities:	'	'
Accounts payable	16,462	10,790
Accrued expenses	62,454	62,996
Deferred revenue	1,044	1,009
Common stock warrant liabilities	10,250	0
Current portion of long-term debt	4,189	4,924
Total current liabilities	94,399	79,719
Long-term debt, less current portion	64,115	49,978
Other long-term liabilities	36,039	38,784
Deferred income tax liabilities	1,998	1,870
Redeemable preferred stock, $0.0001 par value; 20,000 authorized at March 31, 2014 and December 31, 2013; 3,319 shares issued and outstanding at both March 31, 2014 and December 31, 2013	23,603	23,603
Stockholders’ equity:	'	'
Common stock, $0.0001 par value; 200,000 authorized at March 31, 2014 and December 31, 2013; 97,675 and 97,599 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	10	10
Treasury stock, 19 shares	-97	-97
Additional paid-in capital	404,514	403,568
Accumulated other comprehensive loss	4,056	3,877
Accumulated deficit	-242,355	-235,682
Total stockholders’ equity	166,128	171,676
Total liabilities and stockholders’ equity	$386,282	$365,630

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Redeemable preferred stock, par value	$0.00	$0.00
Redeemable preferred stock, shares authorized	20,000,000	20,000,000
Redeemable preferred stock, shares issued	3,319,000	3,319,000
Redeemable preferred stock, shares outstanding	3,319,000	3,319,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	97,675,000	97,599,000
Common stock, shares outstanding	97,675,000	97,599,000
Treasury stock, shares	19,000	19,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Revenues	$49,173	$50,443
Cost of revenues	15,433	17,270
Amortization of acquired intangible assets	446	431
Gross profit	33,294	32,742
Operating expenses:	'	'
Research and development	4,181	3,682
Sales and marketing	18,059	18,495
General and administrative	14,222	11,130
Amortization of acquired intangible assets	758	793
Restructuring expenses	776	0
Total operating expenses	37,996	34,100
Operating loss	-4,702	-1,358
Other income (expense):	'	'
Interest income	3	2
Interest expense	-1,688	-695
Other income (expense), net	383	-650
Total other income (expense)	-1,302	-1,343
Pretax net loss	-6,004	-2,701
Income tax provision (benefit)	669	-52
Net loss	($6,673)	($2,649)
Net loss per common share:	'	'
Basic and diluted net loss per share (In dollars per share)	($0.07)	($0.03)
Weighted-average shares used in computing net loss per share:	'	'
Basic and diluted (in shares)	96,838	95,826

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Statement of Comprehensive Income [Abstract]	'	'
Net loss	($6,673)	($2,649)
Foreign currency translation adjustments	-179	-4,485
Comprehensive loss	($6,852)	($7,134)

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities:	'	'
Net loss	($6,673)	($2,649)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	4,851	6,259
Stock-based compensation	944	1,184
Interest expense related to amortization of debt discount and debt issuance costs	430	129
Provision for doubtful accounts	178	57
Provision for excess and obsolete inventory	713	1,698
Deferred income tax (benefit) expense	106	-204
Other noncash items	-335	285
Changes in operating assets and liabilities:	'	'
Restricted cash	-17,750	0
Accounts receivable	2,560	-674
Inventories	-1,239	-3,387
Prepaid expenses and other current assets	-72	394
Other assets	-128	39
Accounts payable	4,036	897
Accrued expenses and other	-3,984	-4,318
Deferred revenues	-18	-46
Net cash used in operating activities	-16,381	-336
Investing activities:	'	'
Purchases of property and equipment	-1,794	-2,519
Purchase of intangible assets	0	-250
Cash received from sale of assets	300	0
Net cash used in investing activities	-1,494	-2,769
Financing activities:	'	'
Borrowings under lines of credit	39,021	34,669
Repayments under lines of credit	-36,601	-33,497
Principal payments on capital lease obligations	-120	-124
Proceeds from notes payable	19,500	0
Principal payments on notes payable	-1,488	-630
Net cash provided by financing activities	20,312	418
Effect of exchange rate changes on cash	-18	-261
Net increase (decrease) in cash	2,419	-2,948
Cash at beginning of period	21,345	22,241
Cash at end of period	23,764	19,293
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	1,189	936
Cash paid for income taxes	142	958
Purchases of property and equipment in accounts payable	1,711	3,768
Non-cash debt discount	500	0
Initial fair value of warrant liability	$10,368	$0

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
The Company and Basis of Presentation	'
	The Company and Basis of Presentation
	The Company
	Alphatec Holdings, Inc. (“Alphatec”, “Alphatec Holdings” or the “Company”), through its wholly owned subsidiary, Alphatec Spine, Inc. and its subsidiaries (“Alphatec Spine”), designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through the distribution channels of Alphatec Spine and its affiliate, Scient’x S.A.S., and its subsidiaries (“Scient’x”), via a direct sales force in Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In South America and Latin America, the Company conducts its operations through its Brazilian subsidiary, Cibramed Productos Medicos. In Asia, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. and its subsidiaries (“Alphatec Pacific”), via a direct sales force and independent distributors, and through distributors in other parts of Asia and Australia.
	Basis of Presentation
	The accompanying condensed consolidated balance sheet as of December 31, 2013, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual audited financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made in this quarterly report on Form 10-Q are adequate to make the information not misleading. The interim unaudited condensed consolidated financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the financial position and results of operations for the periods presented. All such adjustments are of a normal and recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2013, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 that was filed with the SEC on March 20, 2014.
	Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014, or any other future periods.
	The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. A going concern basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of its liabilities in the normal course of business. Based on the Company’s annual operating plan, management believes that its existing cash and cash equivalents of $23.8 million combined with anticipated cash flow from operations in 2014 and other working capital, excluding common stock warrant liability, of $27.5 million at March 31, 2014 and the Company's available borrowings under the credit facilities with MidCap Financial, LLC ("MidCap") and Deerfield Private Design Fund II, L.P., Deerfield Private Design International II, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special Situations International Master Fund, L.P. (collectively, “Deerfield”), will be sufficient to fund its cash requirements, including the required payments due under the Orthotec litigation settlement (Note 6), through at least March 31, 2015.
	The Company’s amended credit facility (the “Amended Credit Facility”) with MidCap contains financial covenants consisting of a monthly fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio (see Note 5). Based on the Company’s current operating plan, the Company believes that it will be in compliance with the financial covenants of the Amended Credit Facility at least through March 31, 2015. However, there is no assurance that the Company will be able to do so. If the Company is not able to achieve its planned revenue or incurs costs in excess of its forecasts, it may be required to substantially reduce discretionary spending and it could be in default of the Amended Credit Facility, which would require a waiver from MidCap. There can be no assurance that such a waiver could be obtained, that the Amended Credit Facility could be successfully renegotiated or that the Company could modify its operations to maintain liquidity. If the Company is unable to obtain any required waivers or amendments, MidCap would have the right to exercise remedies specified in the Amended Credit Facility, including accelerating the repayment of debt obligations. The Company may be forced to seek additional financing, which may include additional debt and/or equity financing or funding through other third party agreements. There can be no assurances that additional financing would be available on acceptable terms or available at all. Furthermore, any equity financing may result in dilution to existing stockholders and any debt financing may include restrictive covenants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	The Company’s significant accounting policies are described in Note 2 to its audited consolidated financial statements for the year ended December 31, 2013, which are included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 20, 2014. Except as discussed below, these accounting policies have not significantly changed during the three months ended March 31, 2014.
	Restricted Cash
	In March 2014, the Company borrowed and set aside cash for the payment of a portion of the Orthotec litigation settlement (see Note 6) as limited by the terms of the facility agreement that we entered into with Deerfield on March 17, 2014 (see Note 5). The Company classified this cash as restricted, because it may not be used for purposes other than payments of amounts due under the Orthotec litigation settlement agreement.
	Warrants for Common Stock
	Common stock warrants that contain compliance covenants and cash payment obligations are classified as common stock warrant liabilities on the consolidated balance sheet. The Company records the warrant liability at fair value and adjust the carrying value of these common stock warrants to their estimated fair value at each reporting date with the increases or decreases in the fair value of such warrants at each reporting date recorded as other income (expense) in the consolidated statement of operations.
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments became effective for the Company beginning January 1, 2014. The Company adopted this guidance and the adoption did not have any impact on the Company's financial statements.

Select_Balance_Sheet_Details

Select Balance Sheet Details	3 Months Ended
	Mar. 31, 2014
Balance Sheet Related Disclosures [Abstract]	'
Select Balance Sheet Details	'
	Select Balance Sheet Details
	Accounts Receivable, net
	Accounts receivable, net consist of the following (in thousands):
		March 31, 2014				December 31, 2013
	Accounts receivable	$	39,968			$	42,443
	Allowance for doubtful accounts	(1,130		)		(1,048		)
	Accounts receivables, net	$	38,838			$	41,395
	Inventories, net
	Inventories, net consist of the following (in thousands):
		March 31, 2014										December 31, 2013
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	3,996			$	—			$	3,996	$	4,375	$	—		$	4,375
	Work-in-process	645				—				645		531		—			531
	Finished goods	60,852				(22,951		)		37,901		60,979		(23,946		)	37,033
	Inventories	$	65,493			$	(22,951	)		$	42,542	$	65,885	$	(23,946	)	$	41,939
	Property and Equipment, net
	Property and equipment, net consist of the following (in thousands except as indicated):
		Useful lives		March 31, 2014				December 31, 2013
		(in years)
	Surgical instruments	4		$	62,602			$	62,636
	Machinery and equipment	7		14,414				14,692
	Computer equipment	3		3,143				3,357
	Office furniture and equipment	5		3,861				3,703
	Leasehold improvements	various		3,733				4,161
	Building	39		77				52
	Land	n/a		11				10
	Construction in progress	n/a		1,270				1,228
				89,111				89,839
	Less accumulated depreciation and amortization			(60,975		)		(61,809		)
	Property and equipment, net			$	28,136			$	28,030
	Total depreciation expense was $3.3 million and $3.5 million for the three months ended March 31, 2014 and 2013, respectively. At March 31, 2014, assets recorded under capital leases of $2.4 million were included in the machinery and equipment balance. At December 31, 2013, assets recorded under capital leases of $1.8 million were included in the machinery and equipment balance and $0.6 million in construction in progress balance. Amortization of assets under capital leases was included in depreciation expense.
	Intangible Assets, net
	Intangible assets, net consist of the following (in thousands except for useful lives):
		Useful lives		March 31, 2014				December 31, 2013
		(in years)
	Developed product technology	8-Mar		$	23,641			$	23,633
	Distribution rights	3		2,388				2,343
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		16,716				17,686
	Core technology	10		5,140				5,137
	Trademarks and trade names	9-Mar		3,922				3,920
	Customer-related	15-Dec		22,171				22,161
	Distribution network	12-Oct		4,027				4,027
	Physician education programs	10		3,163				3,160
	Supply agreement	10		225				225
				82,397				83,296
	Less accumulated amortization			(45,221		)		(44,232		)
	Intangible assets, net			$	37,176			$	39,064
	Total amortization expense was $1.6 million and $2.7 million for the three months ended March 31, 2014 and 2013, respectively.
	Future amortization expense related to intangible assets subject to amortization are as follows (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	4,739
	2015	6,060
	2016	5,537
	2017	5,240
	2018	3,288
	Thereafter	12,312
		$	37,176
	Accrued Expenses
	Accrued expenses consist of the following (in thousands):
		March 31, 2014				December 31, 2013
Legal	$	1,376			$	2,139
Accounting	782				928
Severance	173				297
Restructuring	9,307				9,170
Sales milestones	1,958				1,828
Accrued taxes	924				1,120
Deferred rent	1,073				1,163
Royalties	2,436				2,347
Commissions	4,376				6,180
Payroll and related	10,196				9,369
Litigation settlements	22,708				22,600
Other	7,145				5,855
Total accrued expenses	$	62,454			$	62,996
Goodwill
The changes in the carrying amount of goodwill from December 31, 2013 through March 31, 2014 are as follows (in thousands):
Balance at December 31, 2013	$	183,004
Effect of foreign exchange rate on goodwill	84
Balance at March 31, 2014	$	183,088

License_and_Supply_Agreements

License and Supply Agreements	3 Months Ended
	Mar. 31, 2014
License and Supply Agreements [Abstract]	'
License and Supply Agreements	'
	License and Supply Agreements
	The Company’s license and developmental consulting agreements are described in Note 5 to its audited consolidated financial statements for the year ended December 31, 2013, which are included in its Annual Report on Form 10-K which was filed with the SEC on March 20, 2014.

Debt

Debt	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	MidCap Facility Agreement
	On August 30, 2013, the Company entered into an Amended and Restated Credit, Security and Guaranty Agreement (the "Amended Credit Facility") with MidCap. The Amended Credit Facility amended and restated the prior credit facility that the Company had with MidCap (the "Credit Facility").
	Pursuant to the Amended Credit Facility, the Company increased the borrowing limit from $50 million to $73 million. The Company also extended the maturity to August 2016. The Amended Credit Facility consists of a $28 million term loan drawn at closing with a $5 million delayed draw within 12 months, for a total term loan maximum borrowing of $33 million and a revolving line of credit with a maximum borrowing base of $40 million. The Company used the term loan proceeds of $28 million to repay a portion of the outstanding balance on the prior revolving line of credit. The $5 million delayed draw was borrowed on April 1, 2014.
	The term loan interest rate is priced at the London Interbank Offered Rate ( "LIBOR") plus 8.0%, subject to a 9.5% floor, and the revolving line of credit interest rate remains priced at LIBOR plus 6.0%, reset monthly. At March 31, 2014, the revolving line of credit carried an interest rate of 6.2% and the term loan carries an interest rate of 9.5%. The borrowing base is determined, from time to time, based on the value of domestic eligible accounts receivable and domestic eligible inventory. As collateral for the Amended Credit Facility, the Company granted MidCap a security interest in substantially all of its assets, including all accounts receivable and all securities evidencing its interests in its subsidiaries. In addition to monthly payments of interest, monthly repayments of $0.3 million of the principal for the term loan are due beginning in October 2013 through maturity, with the remaining principal due upon maturity.
	In connection with the execution of the Amended Credit Facility, the Company incurred an additional $0.4 million in costs that were capitalized as debt issuance costs within the unaudited consolidated balance sheets as of September 30, 2013. At March 31, 2014, $0.7 million remains as unamortized debt issuance costs related to the prior and Amended Credit Facility within the unaudited consolidated balance sheets, which will be amortized over the remaining term of the Amended Credit Facility.
	The Amended Credit Facility includes traditional lending and reporting covenants including a fixed charge coverage ratio, a senior leverage ratio and a total leverage ratio to be maintained by the Company. The Amended Credit Facility also includes several potential events of default, such as payment default and insolvency conditions, which could cause interest to be charged at a rate which is up to five percentage points above the rate effective immediately before the event of default or result in MidCap’s right to declare all outstanding obligations immediately due and payable.
	In January 2013, the Company entered into a limited waiver and limited consent agreement with MidCap (the “Waiver”). Under the Waiver, MidCap gave the Company its consent to waive certain provisions of the Credit Facility in connection with the acquisition of Phygen and related to the maintenance of cash balances in the U.S. In February 2013, the Company and MidCap entered into a first amendment to the Credit Facility (the "First Amendment to the Credit Facility”). The First Amendment to the Credit Facility allowed the Company to exclude payments related to the Phygen acquisition and the settlement agreement with Cross Medical Products, LLC (“Cross”) from calculation of the fixed charge coverage ratio and the senior leverage ratio. In conjunction with the First Amendment to the Credit Facility, the Company paid MidCap a fee of $0.1 million. In July 2013, the Company entered into a second limited waiver and limited consent agreement with MidCap (the “Second Waiver”). Under the Second Waiver, MidCap gave the Company its consent to waive certain provisions of the Credit Facility related to the maintenance of cash balances in the U.S. for past periods through September 30, 2013. On August 30, 2013, the Company entered into the Amended Credit Agreement with MidCap.
	On March 17, 2014, the Company entered into a first amendment to the Amended Credit Facility with MidCap (the "First Amendment to the Amended Credit Facility"). Under the First Amendment to the Amended Credit Facility, MidCap gave the Company its consent to enter into the Facility Agreement (defined below) and make settlement payments in connection with the Orthotec litigation. The First Amendment to the Amended Credit Facility also added a total leverage ratio financial covenant. The Company was in compliance with all of the covenants of the Amended Credit Facility, as amended, as of March 31, 2014.
	Deerfield Facility Agreement
	On March 17, 2014, the Company entered into a facility agreement (the “Facility Agreement”) with Deerfield, pursuant to which Deerfield agreed to loan the Company up to $50 million, subject to the terms and conditions set forth in the Facility Agreement. Under the terms of the Facility Agreement, the Company has the option, but is not required, upon certain conditions to draw the entire amount available under the Facility Agreement, at any time until January 30, 2015 (the “Draw Period”), provided that the initial draw be used for a portion of the payments made in connection with the Orthotec settlement described below. Following such initial draw down, the Company may draw down additional amounts under the Facility Agreement up to an aggregate $15 million for working capital or general corporate purposes in $2.5 million increments until the end of the Draw Period. The Company has agreed to pay Deerfield, upon each disbursement of funds under the Facility Agreement, a transaction fee equal to 2.5% of the principal amount of the funds disbursed. Amounts borrowed under the Facility Agreement bear interest at a rate of 8.75% per annum and are payable on the third, fourth and fifth anniversary date of the first amount borrowed under the Facility Agreement, with the final payment due on March 20, 2019.
	The Facility Agreement also contains various representations and warranties, and affirmative and negative covenants, customary for financings of this type, including restrictions on the ability of the Company and its subsidiaries to incur additional indebtedness or liens on its assets, except as permitted under the Facility Agreement. As security for our repayment of our obligations under the Facility Agreement, we granted to Deerfield a security interest in substantially all of our property and interests in property that are subordinated to the security interest granted under the Amended Credit Facility.
	In connection with the execution of the Facility Agreement on March 17, 2014, the Company issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock (the “Initial Warrants”) (See Note 8). Additionally, each disbursement borrowing under the Facility Agreement shall be accompanied by the issuance to Deerfield of warrants to purchase up to 10,000,000 shares of the Company’s common stock, in proportion to the amount of draw compared to the total $50 million facility (the "Draw Warrants") (See Note 8).
	On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund its 2014 Orthotec settlement payment obligations. The $0.5 million transaction fee is recorded as a debt discount and is being amortized over the term of the draw, which ends March 20, 2019. In connection with this borrowing, the Company issued 4,000,000 Draw Warrants, which were valued at $4.7 million and recorded as a debt discount and is being amortized over the term of the $20 million draw. Additionally, $2.3 million of the Initial Warrants were reclassified as a debt discount and are being amortized through interest expense over the term of the debt using the effective interest method. Orthotec settlement payments of $1.75 million were made in March 2014, leaving remaining proceeds of $17.8 million, which were classified as restricted cash as of March 31, 2014, as their use is limited under the terms of the Facility Agreement for the payments of amounts due under the Orthotec litigation settlement agreement. The amounts borrowed under the Facility Agreement are due in three equal annual payments beginning March 20, 2017.
	Principal payments on debt are as follows as of March 31, 2014 (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	2,997
	2015	3,000
	2016	48,501
	2017	6,667
	2018	6,667
	Thereafter	6,666
	Total	74,498
	Add: capital lease principal payments	1,216
	Less: debt discount	(7,410		)
	Total	68,304
	Less: current portion of long-term debt	(4,189		)
	Long-term debt, net of current portion	$	64,115

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Leases
	The Company leases certain equipment under capital leases which expire on various dates through June 2017. The leases bear interest at rates ranging from 6.6% to 9.6%, are generally due in monthly principal and interest installments and are collateralized by the related equipment. The Company also leases its buildings and certain equipment and vehicles under operating leases which expire on various dates through January 2019. Future minimum annual lease payments under such leases are as follows (in thousands):
	Year Ending December 31,	Operating		Capital
	Remainder of 2014	$	2,452	$	391
	2015	2,724		461
	2016	1,424		422
	2017	247		82
	2018	58		—
	Thereafter	2		—
		$	6,907	1,356
	Less: amount representing interest			(140		)
	Present value of minimum lease payments			1,216
	Current portion of capital leases			(442		)
	Capital leases, less current portion			$	774
	Rent expense under operating leases for the three months ended March 31, 2014 and 2013 was $1.0 million and $1.0 million, respectively.
	Litigation
	In 1998, Eurosurgical, a French company in the business of sales and marketing of spinal implants, entered into a distribution agreement for the United States, Mexico, Canada, India and Australia with Orthotec, LLC, a California company (“Orthotec”). In 2004, Orthotec sued Eurosurgical in connection with a contractual dispute and a final $9 million judgment was entered against Eurosurgical by a California court in 2006. In 2007, following a default judgment, a federal court in California declared Eurosurgical liable to Orthotec for $30 million in connection with an intellectual property dispute. In 2006, Eurosurgical’s European assets were ultimately acquired by Surgiview, SAS, ("Surgiview"), in a sale agreement, ("the Partial Sale Agreement"), approved by a French court. After this sale, Surgiview became a subsidiary of Scient’x in 2006. Orthotec attempted to recover on Eurosurgical’s obligations by filing a motion in a California court to add Surgiview to the judgment against Eurosurgical on theories including successor liability and fraudulent conveyance. In February 2007, the California court denied Orthotec’s motion, indicating that Orthotec had not carried its burdens of proof. Orthotec chose to not proceed with a further hearing in September 2007.
	In June 2004, HealthpointCapital (Luxembourg) I S.à.r.l. acquired a minority (33.1 percent) interest in Scient’x. In July 2005, Scient’x acquired an approximate 73 percent interest in Surgiview. At that time, HealthpointCapital Partners, L.P. (through a Luxembourg subsidiary) held a minority interest in Scient’x, which in turn held an interest in Surgiview, but HealthpointCapital Partners II, L.P. had no ownership interest in Scient’x or Surgiview. On November 21, 2007, more than a year after the Partial Sale Agreement was executed, HealthpointCapital Partners II, L.P. acquired majority ownership of Scient’x. In May 2008, after the acquisition of Scient’x by HealthpointCapital in 2007, Orthotec sued Scient’x, Surgiview, HealthpointCapital LLC and certain former directors of Scient’x (who also serve on the Company’s board) in a new action in California state court in which it sought (in addition to damages related to other causes of action and punitive damages related thereto) to have the defendants bear responsibility for the $39 million in judgments that had been assessed against Eurosurgical, which, together with interest is now greater than $70 million. On February 10, 2014, the jury reached a verdict in which Surgiview was found to have transferred assets for less than fair market value in connection with Surgiview’s purchase of certain assets of Eurosurgical, and to have interfered with certain contractual rights of Orthotec. Although a formal judgment was never entered, the jury awarded monetary damages in the amount of $47.9 million, plus interest, against Surgiview related to various causes of action alleged by Orthotec.
	In addition, also in May 2008, a similar action was filed in New York against HealthpointCapital, HealthpointCapital LLC, HealthpointCapital Partners, L.P., HealthpointCapital Partners II, L.P., Scient’x and two former directors of Scient’x (who also serve on the Company’s board), in which Orthotec sought, in addition to damages related to other causes of action and punitive damages related thereto, to have the defendant’s bear responsibility for the $39 million in judgments that had been assessed against Eurosurgical, which, together with interest is now greater than $70 million.
	On March 15, 2014, the Company, Orthotec, LLC and certain other parties, including certain directors and affiliates of the Company, entered into a binding term sheet to settle all legal matters between Orthotec and the Company and its directors and affiliates.  Pursuant to the binding term sheet, the Company has agreed to pay Orthotec $49 million in cash, with initial cash payments of $1.75 million paid in March 2014 and $15.75 million paid on April 10, 2014. The remaining $31.5 million will be paid to Orthotec in installments of $1.1 million paid quarterly, beginning in the fourth quarter of 2014. HealthpointCapital has agreed to contribute $5 million to the $49 million settlement amount. In addition, a 7% simple interest rate will accrue on the unpaid portion of the $31.5 million. All accrued interest is not payable until the $49 million is paid, and such accrued interest shall be paid in $1.1 million installments each quarter. This settlement will result in mutual releases of all claims and the dismissal of all Orthotec-related litigation matters involving the Company, its directors and affiliates.
	On August 10, 2010, a purported securities class action complaint was filed in the United States District Court for the Southern District of California on behalf of all persons who purchased the Company's common stock between December 19, 2009 and August 5, 2010 against the Company and certain of its directors and officers alleging violations of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. On February 17, 2011, an amended complaint was filed against the Company and certain of its directors and officers adding alleged violations of the Securities Act of 1933, as amended. HealthpointCapital, Jefferies & Company, Inc., Canaccord Adams, Inc., Cowen and Company, Inc., and Lazard Capital Markets LLC are also defendants in this action. The complaint alleges that the defendants made false or misleading statements, as well as failed to disclose material facts, about the Company’s business, financial condition, operations and prospects, particularly relating to the Scient’x transaction and our financial guidance following the closing of the acquisition. The complaint seeks unspecified monetary damages, attorneys’ fees, and other unspecified relief. The Company believe that the claims are without merit and it intends to vigorously defend itself against this complaint. However, the outcome of the litigation cannot be predicted at this time and any outcome that is adverse to the Company, regardless of who the defendant is, could have a significant adverse effect on its financial condition and results of operations.
	On August 25, 2010, an alleged shareholder of the Company filed a derivative lawsuit in the Superior Court of California, San Diego County, purporting to assert claims on behalf of the Company against all of its directors and certain of its officers and HealthpointCapital. Following the filing of this complaint, similar complaints were filed in the same court and in the U.S. District Court for the Southern District of California against the same defendants containing similar allegations. The complaint filed in federal court was dismissed by the plaintiff without prejudice in July 2011. The state court complaints have been consolidated into a single action and the Company has been named as a nominal defendant in the consolidated action. Each complaint alleges that the Company’s directors and certain of its officers breached their fiduciary duties to the Company related to the Scient’x transaction, and by making allegedly false statements that led to unjust enrichment of HealthpointCapital and certain of the Company’s directors. The complaints seek unspecified monetary damages and an order directing the Company to adopt certain measures purportedly designed to improve its corporate governance and internal procedures. On January 8, 2014, the parties reached an agreement in principle to resolve all claims in exchange for corporate governance reforms and payment of attorneys’ fees in the amount of $5.25 million, to be paid by the Company’s and HeathpointCapital’s respective insurance carriers. The Company believes the claims are without merit and, subject to final approval of any settlement, intends to vigorously defend itself against these complaints. No assurances can be given as to the timing or outcome of this lawsuit.
	At March 31, 2014, the probable outcome of any of the aforementioned litigation matters that have not reached a settlement cannot be determined nor can the Company estimate a range of potential loss. Accordingly, in accordance with the authoritative guidance on the evaluation of contingencies, the Company has not recorded an accrual related to any litigation matters that have not reached a settlement. The Company is and may become involved in various other legal proceedings arising from its business activities. While management does not believe the ultimate disposition of these matters will have a material adverse impact on the Company’s consolidated results of operations, cash flows or financial position, litigation is inherently unpredictable, and depending on the nature and timing of these proceedings, an unfavorable resolution could materially affect the Company’s future consolidated results of operations, cash flows or financial position in a particular period.
	Royalties
	The Company has entered into various intellectual property agreements requiring the payment of royalties based on the sale of products that utilize such intellectual property. These royalties primarily relate to products sold by Alphatec Spine and are calculated either as a percentage of net sales or in one instance on a per-unit sold basis. Royalties are included on the accompanying condensed consolidated statement of operations as a component of cost of revenues.

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	Basic earnings per share (“EPS”) is calculated by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted EPS is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding for the period and the weighted average number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive (in thousands, except per share data):
		Three Months Ended
		March 31,
		2014				2013
	Numerator:
	Net loss	$	(6,673	)		$	(2,649	)
	Denominator:
	Weighted average common shares outstanding	97,668				96,701
	Weighted average unvested common shares subject to repurchase	(830		)		(875		)
	Weighted average common shares outstanding—basic	96,838				95,826
	Effect of dilutive securities:
	Options, warrants and restricted share awards	—				—
	Weighted average common shares outstanding—diluted	96,838				95,826
	Net loss per common share:
	Basic and diluted net loss per share	$	(0.07	)		$	(0.03	)
	The weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Options to purchase common stock	5,378			3,939
	Unvested restricted share awards	830			875
	Warrants to purchase common stock	10,844			594
	Total	17,052			5,408

Equity_Transactions

Equity Transactions	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Equity Transactions	'
	Equity Transactions
	Warrants
	In connection with the execution of the Facility Agreement, on March 17, 2014, the Company issued to Deerfield warrants to purchase an aggregate of 6,250,000 shares of the Company’s common stock immediately exercisable at an exercise price equal to $1.39 (the “Initial Warrants”) expiring on March 17, 2020. The number of shares of common stock into which the Initial Warrants are exercisable and the exercise price will be adjusted to reflect any stock splits, payment of stock dividends, recapitalizations, reclassifications or other similar adjustments in the number of outstanding shares of the Company’s common stock. The warrants have the same dividend rights to the same extent as if the warrants had been exercised for shares of common stock.
	Each disbursement borrowing under the Facility Agreement shall be accompanied by the issuance to Deerfield of additional warrants to purchase up to an aggregate of 10,000,000 shares of the Company’s common stock, at an exercise price equal to the lesser of the Initial Warrant exercise price or the average daily volume weighted average price per share of the Company’s common stock for the 15 days following the request for borrowing (the “Draw Warrants”). The number of Draw Warrants issued for each draw will be in proportion to the amount of draw compared to the total $50 million facility.
	The Initial Warrants were valued on March 17, 2014 using a Black-Scholes option pricing model that resulted in a value of $5.7 million, which was recorded as a current liability with an offset to a deferred charge asset and will be amortized on a straight line basis through interest expense over the term of the Facility Agreement commitment period ending January 30, 2015. To the extent the Company draws on the $50 million Facility Agreement, a proportionate amount of the unamortized current deferred charge will be reclassified as debt discount and amortized through interest expense over the term of the debt using the effective interest method.
	On March 20, 2014, the Company made an initial draw of $20 million under the Facility Agreement and received net proceeds of $19.5 million to fund its 2014 Orthotec settlement payment obligations. In connection with this borrowing, the Company issued Draw Warrants to purchase 4,000,000 shares of common stock at an exercise price of $1.39. The Draw Warrants were valued at $4.7 million using the Black-Scholes option pricing model, which was recorded as a current liability with an offset to debt discount. In connection with the $20 million draw, $2.3 million of the deferred charge recorded upon the issuance of the Initial Warrants was reclassified as a debt discount.
	As of March 31, 2014, the 10,250,000 outstanding Initial Warrants and Draw Warrants were revalued to their fair value with a charge to other income of $0.1 million. The warrant liability of $10.3 million is recorded as common stock warrant liabilities within current liabilities on the condensed consolidated balance sheet as of March 31, 2014.
	At March 31, 2014, our outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:
		March 31, 2014
	Risk-free interest rate	1.9	%
	Dividend yield	—	%
	Expected volatility	74	%
	Expected life (years)	6

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	To calculate its interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. In addition, the effect of changes in enacted tax laws or rates or tax status is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in foreign jurisdictions, permanent and temporary differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained or as the tax environment changes.
	The Company recognizes interest and penalties related to uncertain tax positions as a component of the income tax provision. The Company’s unrecognized tax benefits increased less than $0.1 million during the three months ended March 31, 2014. The increase in unrecognized tax benefits during the three months ended March 31, 2014 was primarily related to an increase related to state research credits and uncertain tax positions within the Company’s foreign subsidiaries, partially offset by changes in prior year uncertain tax positions within the Company's foreign subsidiaries. The unrecognized tax benefits at March 31, 2014 were $7.9 million. With the facts and circumstances currently available to the Company, it is reasonably possible that the amount that could reverse over the next 12 months is insignificant. Additionally, the French restructuring (see Note 11) may result in limitations on the Company’s ability to utilize its French net operating loss carryforwards to offset future taxable income.
	The income tax provision consists primarily of income tax provisions related to state income taxes, the tax effect of changes in deferred tax liabilities associated with tax deductible goodwill and operations in other foreign jurisdictions where the Company operates.
	The Company is not currently under examination by the IRS, or by foreign, state or local tax authorities.

Segment_and_Geographical_Infor

Segment and Geographical Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment and Geographical Information	'
	Segment and Geographical Information
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company has one operating and one reportable business segment.
	During the three months ended March 31, 2014 and 2013, the Company operated in two geographic regions, the U.S. and International, which consists of locations outside of the U.S. In the International geographic region, sales in Japan for the three months ended March 31, 2014 totaled $7.7 million, which represented greater than 10 percent of the Company’s consolidated revenues. In the International geographic region, sales in Japan for the three months ended March 31, 2013 totaled $6.4 million, which represented greater than 10 percent of the Company’s consolidated revenues.
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	United States	$	32,050	$	33,062
	International	17,123		17,381
	Total consolidated revenues	$	49,173	$	50,443
	Total assets by region were as follows (in thousands):
		March 31,		December 31,
		2014		2013
	United States	$	223,667	$	196,383
	International	162,615		169,247
	Total consolidated assets	$	386,282	$	365,630

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	Restructuring
	On September 16, 2013, the Company announced that Scient'x has begun a process to significantly restructure its business operations in France in an effort to improve operating efficiencies and rationalize its cost structure. The restructuring includes a reduction and a further expected reduction in 2014 in Scient'x's workforce and closing of the manufacturing facilities in France. The Company estimates that it will record total costs, including employee severance, social plan benefits and related taxes, facility closing costs, manufacturing transfer costs, and contract termination costs of approximately $11.6 million associated with this restructuring. In accordance with ASC Topic 420, Accounting for Costs Associated with Exit or Disposal Activities, and ASC Topic 712, Non Retirement Postemployment Benefits, the Company has recorded a restructuring charge accrual in accrued expenses of $9.3 million within the condensed consolidated balance sheet as of March 31, 2014. Additionally, the Company has recorded restructuring expenses of $0.8 million within the condensed consolidated statement of operations for the three months ending March 31, 2014. The Company estimates that it will record total severance and benefits of approximately $10.0 million and facility closing and other restructuring costs of approximately $1.6 million. The Company expects to complete all the activities associated with the restructuring activities by the end of the second quarter of 2014, a substantial portion of which will be paid by then.
	Below is a table of the movement (in thousands):
		Accrued Balance at		Expensed		Paid and			Accrued Balance at		Total Costs		Total Expected
		31-Dec-13		March 31, 2014		Other			31-Mar-14		Incurred		Remaining Costs
	Social plan costs	$	9,170	$	287	$	(336	)	$	9,121	$	9,540	$	500
	Other restructuring costs	—		489		(303		)	186		901		700
	Total	$	9,170	$	776	$	(639	)	$	9,307	$	10,441	$	1,200

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	For the three months ended March 31, 2014, the Company incurred expenses of $0.1 million and had a liability of $0.2 million payable to HealthpointCapital, LLC for travel and administrative expenses.
	The Company has entered into indemnification agreements with certain of its directors which are named defendants in the New York Orthotec matter (See Note 6 – Commitments and Contingencies – Litigation). The indemnification agreements require the Company to indemnify these individuals to the fullest extent permitted by applicable law and to advance expenses incurred by them in connection with any proceeding against them with respect to which they may be entitled to indemnification by the Company. For the three months ended March 31, 2014 and 2013, the Company incurred legal expenses of less than $0.1 million and $0.6 million, respectively, in connection with the Company’s indemnification obligations to two former directors of Scient'x in the New York Orthotec matter.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Warrant for Common Stock	'
	Warrants for Common Stock
	Common stock warrants that contain compliance covenants and cash payment obligations are classified as common stock warrant liabilities on the consolidated balance sheet. The Company records the warrant liability at fair value and adjust the carrying value of these common stock warrants to their estimated fair value at each reporting date with the increases or decreases in the fair value of such warrants at each reporting date recorded as other income (expense) in the consolidated statement of operations.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued guidance on a parent company’s accounting for the cumulative translation adjustment upon derecognition of a subsidiary or group of assets within a foreign entity. This new guidance requires that the parent release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. The amendments became effective for the Company beginning January 1, 2014. The Company adopted this guidance and the adoption did not have any impact on the Company's financial statements.

Select_Balance_Sheet_Details_T

Select Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2014
Balance Sheet Related Disclosures [Abstract]	'
Accounts Receivable, Net	'
	Accounts receivable, net consist of the following (in thousands):
		March 31, 2014				December 31, 2013
	Accounts receivable	$	39,968			$	42,443
	Allowance for doubtful accounts	(1,130		)		(1,048		)
	Accounts receivables, net	$	38,838			$	41,395
Inventories, Net	'
	Inventories, net consist of the following (in thousands):
		March 31, 2014										December 31, 2013
		Gross				Reserve for				Net		Gross		Reserve for			Net
						excess and								excess and
						obsolete								obsolete
	Raw materials	$	3,996			$	—			$	3,996	$	4,375	$	—		$	4,375
	Work-in-process	645				—				645		531		—			531
	Finished goods	60,852				(22,951		)		37,901		60,979		(23,946		)	37,033
	Inventories	$	65,493			$	(22,951	)		$	42,542	$	65,885	$	(23,946	)	$	41,939
Property and Equipment, Net	'
	Property and equipment, net consist of the following (in thousands except as indicated):
		Useful lives		March 31, 2014				December 31, 2013
		(in years)
	Surgical instruments	4		$	62,602			$	62,636
	Machinery and equipment	7		14,414				14,692
	Computer equipment	3		3,143				3,357
	Office furniture and equipment	5		3,861				3,703
	Leasehold improvements	various		3,733				4,161
	Building	39		77				52
	Land	n/a		11				10
	Construction in progress	n/a		1,270				1,228
				89,111				89,839
	Less accumulated depreciation and amortization			(60,975		)		(61,809		)
	Property and equipment, net			$	28,136			$	28,030
Intangible Assets, Net	'
	Intangible assets, net consist of the following (in thousands except for useful lives):
		Useful lives		March 31, 2014				December 31, 2013
		(in years)
	Developed product technology	8-Mar		$	23,641			$	23,633
	Distribution rights	3		2,388				2,343
	Intellectual property	5		1,004				1,004
	License agreements	7-Jan		16,716				17,686
	Core technology	10		5,140				5,137
	Trademarks and trade names	9-Mar		3,922				3,920
	Customer-related	15-Dec		22,171				22,161
	Distribution network	12-Oct		4,027				4,027
	Physician education programs	10		3,163				3,160
	Supply agreement	10		225				225
				82,397				83,296
	Less accumulated amortization			(45,221		)		(44,232		)
	Intangible assets, net			$	37,176			$	39,064
Schedule of Intangible assets, future amortization expense	'
	Future amortization expense related to intangible assets subject to amortization are as follows (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	4,739
	2015	6,060
	2016	5,537
	2017	5,240
	2018	3,288
	Thereafter	12,312
		$	37,176
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of the following (in thousands):
		March 31, 2014				December 31, 2013
	Legal	$	1,376			$	2,139
	Accounting	782				928
	Severance	173				297
	Restructuring	9,307				9,170
	Sales milestones	1,958				1,828
	Accrued taxes	924				1,120
	Deferred rent	1,073				1,163
	Royalties	2,436				2,347
	Commissions	4,376				6,180
	Payroll and related	10,196				9,369
	Litigation settlements	22,708				22,600
	Other	7,145				5,855
	Total accrued expenses	$	62,454			$	62,996
Schedule of Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill from December 31, 2013 through March 31, 2014 are as follows (in thousands):
	Balance at December 31, 2013	$	183,004
	Effect of foreign exchange rate on goodwill	84
	Balance at March 31, 2014	$	183,088

Debt_Tables

Debt (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Principal Payments on Debt	'
	Principal payments on debt are as follows as of March 31, 2014 (in thousands):
	Year Ending December 31,
	Remainder of 2014	$	2,997
	2015	3,000
	2016	48,501
	2017	6,667
	2018	6,667
	Thereafter	6,666
	Total	74,498
	Add: capital lease principal payments	1,216
	Less: debt discount	(7,410		)
	Total	68,304
	Less: current portion of long-term debt	(4,189		)
	Long-term debt, net of current portion	$	64,115

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Annual Lease Payments	'
	Future minimum annual lease payments under such leases are as follows (in thousands):
	Year Ending December 31,	Operating		Capital
	Remainder of 2014	$	2,452	$	391
	2015	2,724		461
	2016	1,424		422
	2017	247		82
	2018	58		—
	Thereafter	2		—
		$	6,907	1,356
	Less: amount representing interest			(140		)
	Present value of minimum lease payments			1,216
	Current portion of capital leases			(442		)
	Capital leases, less current portion			$	774

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Weighted Average Number of Common Shares Outstanding	'
	For purposes of this calculation, common stock subject to repurchase by the Company and options are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive (in thousands, except per share data):
		Three Months Ended
		March 31,
		2014				2013
	Numerator:
	Net loss	$	(6,673	)		$	(2,649	)
	Denominator:
	Weighted average common shares outstanding	97,668				96,701
	Weighted average unvested common shares subject to repurchase	(830		)		(875		)
	Weighted average common shares outstanding—basic	96,838				95,826
	Effect of dilutive securities:
	Options, warrants and restricted share awards	—				—
	Weighted average common shares outstanding—diluted	96,838				95,826
	Net loss per common share:
	Basic and diluted net loss per share	$	(0.07	)		$	(0.03	)
Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share	'
		Three Months Ended
		March 31,
		2014				2013
	Numerator:
	Net loss	$	(6,673	)		$	(2,649	)
	Denominator:
	Weighted average common shares outstanding	97,668				96,701
	Weighted average unvested common shares subject to repurchase	(830		)		(875		)
	Weighted average common shares outstanding—basic	96,838				95,826
	Effect of dilutive securities:
	Options, warrants and restricted share awards	—				—
	Weighted average common shares outstanding—diluted	96,838				95,826
	Net loss per common share:
	Basic and diluted net loss per share	$	(0.07	)		$	(0.03	)
	The weighted-average anti-dilutive securities not included in diluted net loss per share were as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Options to purchase common stock	5,378			3,939
	Unvested restricted share awards	830			875
	Warrants to purchase common stock	10,844			594
	Total	17,052			5,408

Equity_Transactions_Equity_Tra

Equity Transactions Equity Transactions (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Schedule of Assumptions Used	'
	At March 31, 2014, our outstanding warrants were valued using the Black-Scholes option pricing model. This is a Level 3 measurement using the following assumptions:
		March 31, 2014
	Risk-free interest rate	1.9	%
	Dividend yield	—	%
	Expected volatility	74	%
	Expected life (years)	6

Segment_and_Geographical_Infor1

Segment and Geographical Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Revenues Attributed to Geographic Location of Customer	'
	Revenues attributed to the geographic location of the customer were as follows (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	United States	$	32,050	$	33,062
	International	17,123		17,381
	Total consolidated revenues	$	49,173	$	50,443
Schedule of Long Lived Assets by Geographical Areas	'
	Total assets by region were as follows (in thousands):
		March 31,		December 31,
		2014		2013
	United States	$	223,667	$	196,383
	International	162,615		169,247
	Total consolidated assets	$	386,282	$	365,630

Restructuring_Restructuring_Ta

Restructuring Restructuring (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring Reserve by Type of Cost	'
	Below is a table of the movement (in thousands):
		Accrued Balance at		Expensed		Paid and			Accrued Balance at		Total Costs		Total Expected
		31-Dec-13		March 31, 2014		Other			31-Mar-14		Incurred		Remaining Costs
	Social plan costs	$	9,170	$	287	$	(336	)	$	9,121	$	9,540	$	500
	Other restructuring costs	—		489		(303		)	186		901		700
	Total	$	9,170	$	776	$	(639	)	$	9,307	$	10,441	$	1,200

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation - Additional Information (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
	Market
Accounting Policies [Abstract]	'	'	'	'
Number of market for products	50	'	'	'
Cash and cash equivalents	$23,764,000	$21,345,000	$19,293,000	$22,241,000
Anticipated cash flow from operations and other working capital	$27,500,000	'	'	'

Select_Balance_Sheet_Details_A

Select Balance Sheet Details - Accounts Receivable, Net (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Accounts receivable	$39,968	$42,443
Allowance for doubtful accounts	-1,130	-1,048
Accounts receivables, net	$38,838	$41,395

Select_Balance_Sheet_Details_I

Select Balance Sheet Details - Inventories, Net (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Raw materials, Gross	$3,996	$4,375
Work-in-process, Gross	645	531
Finished goods, Gross	60,852	60,979
Inventory, Gross, Total	65,493	65,885
Finished goods, Reserve for excess and obsolete	-22,951	-23,946
Inventories, net, Reserve for excess and obsolete	-22,951	-23,946
Raw materials, Net	3,996	4,375
Work-in-process, Net	645	531
Finished goods, Net	37,901	37,033
Inventories, Net	$42,542	$41,939

Select_Balance_Sheet_Details_P

Select Balance Sheet Details - Property and Equipment, Net (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	$89,111,000	$89,839,000
Less accumulated depreciation and amortization	-60,975,000	-61,809,000
Property and Equipment, net	28,136,000	28,030,000
Surgical instruments [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'4 years	'
Property and Equipment, Gross	62,602,000	62,636,000
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Capital Leased Assets, Gross	2,400,000	1,800,000
Useful lives	'7 years	'
Property and Equipment, Gross	14,414,000	14,692,000
Computer equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'3 years	'
Property and Equipment, Gross	3,143,000	3,357,000
Office furniture and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'5 years	'
Property and Equipment, Gross	3,861,000	3,703,000
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Various Useful lives of property and equipments	'various	'
Property and Equipment, Gross	3,733,000	4,161,000
Building [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Useful lives	'39 years	'
Property and Equipment, Gross	77,000	52,000
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	11,000	10,000
Construction in progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Capital Leased Assets, Gross	'	600,000
Property and Equipment, Gross	$1,270,000	$1,228,000

Select_Balance_Sheet_Details_A1

Select Balance Sheet Details - Additional Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Balance Sheet Related Disclosures [Abstract]	'	'
Total depreciation expense	$3.30	$3.50
Total amortization expense	$1.60	$2.70

Select_Balance_Sheet_Details_I1

Select Balance Sheet Details - Intangible Assets, Net (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	$82,397	$83,296
Less accumulated amortization	-45,221	-44,232
Intangible assets, net	37,176	39,064
Developed product technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	23,641	23,633
Developed product technology [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'3 years	'
Developed product technology [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'8 years	'
Distribution rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'3 years	'
Intangible assets, Gross	2,388	2,343
Intellectual property [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'5 years	'
Intangible assets, Gross	1,004	1,004
License agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	16,716	17,686
License agreements [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'1 year	'
License agreements [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'7 years	'
Core technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Intangible assets, Gross	5,140	5,137
Trademarks and trade names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	3,922	3,920
Trademarks and trade names [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'3 years	'
Trademarks and trade names [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'9 years	'
Customer-related [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	22,171	22,161
Customer-related [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'12 years	'
Customer-related [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'15 years	'
Distribution network [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible assets, Gross	4,027	4,027
Distribution network [Member] | Minimum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Distribution network [Member] | Maximum [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'12 years	'
Physician education programs [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Intangible assets, Gross	3,163	3,160
Supply Agreement [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Useful lives	'10 years	'
Intangible assets, Gross	$225	$225

Select_Balance_Sheet_Details_S

Select Balance Sheet Details - Schedule of Intangible assets, future amortization expense (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'
Remainder of 2014	$4,739
2015	6,060
2016	5,537
2017	5,240
2018	3,288
Thereafter	12,312
Total	$37,176

Select_Balance_Sheet_Details_S1

Select Balance Sheet Details Select Balance Sheet Details - Accrued Expense (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]	'	'
Legal	$1,376	$2,139
Accounting	782	928
Severance	173	297
Restructuring	9,307	9,170
Sales milestones	1,958	1,828
Accrued taxes	924	1,120
Deferred rent	1,073	1,163
Royalties	2,436	2,347
Commissions	4,376	6,180
Payroll and related	10,196	9,369
Litigation settlements	22,708	22,600
Other	7,145	5,855
Total accrued expenses	$62,454	$62,996

Select_Balance_Sheet_Details_S2

Select Balance Sheet Details - Schedule of Changes in Carrying Amount of Goodwill (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Goodwill [Roll Forward]	'
Balance at December 31, 2013	$183,004
Effect of foreign exchange rate on goodwill	84
Balance at March 31, 2014	$183,088

Debt_Additional_Information_De

Debt - Additional Information (Details) (USD $)

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

Feb. 28, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 17, 2014

Dec. 31, 2013

Aug. 30, 2013

Sep. 30, 2013

Mar. 31, 2014

Jul. 30, 2013

Mar. 31, 2014

Aug. 30, 2013

Aug. 30, 2013

Aug. 30, 2013

Mar. 31, 2014

Aug. 30, 2013

Mar. 20, 2014

Mar. 31, 2014

Mar. 17, 2014

Mar. 17, 2014

Apr. 01, 2014

Mar. 31, 2014

Apr. 10, 2014

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Amended Credit Facilty with MidCap [Member]

Deerfield [Member]

Deerfield [Member]

Deerfield [Member]

Maximum [Member]

Subsequent Event [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Term Loan [Member]

Term Loan [Member]

Term Loan Drawn On Closing [Member]

Term Loan. Delayed Draw [Member]

Credit Facility [Member]

Credit Facility [Member]

payment

Deerfield [Member]

Amended Credit Facilty with MidCap [Member]

Subsequent Event [Member]

Term Loan. Delayed Draw [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

$73,000,000

'

'

$50,000,000

'

$33,000,000

$28,000,000

$5,000,000

'

$40,000,000

'

'

$50,000,000

'

$5,000,000

'

'

Length of period of term loan delayed draw

'

'

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayments of Lines of Credit

'

36,601,000

33,497,000

'

'

28,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate description

'

'

'

'

'

'

'

'

'

'( "LIBOR") plus 8.0%

'

'

'

'LIBOR plus 6.0%

'

'

'

'

'

'

'

'

Debt, spread on variable rate

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

6.00%

'

'

'

'

'

'

'

'

Floor on interest rate

'

'

'

'

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate of revolving line of credit

'

'

'

'

'

'

'

'

'

9.50%

'

'

'

6.20%

'

'

'

'

'

'

'

'

Term loan payments

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized debt issuance and debt discount costs

'

7,410,000

'

'

'

'

'

700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional interest rate to be charged in the event of default

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amendment fee

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate amount of draw down for working capital

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

Increment amount of draw down for general corporate purposes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

'

'

'

'

Transaction fee as percentage of principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.50%

'

'

'

'

Debt instrument, stated interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.75%

'

'

'

'

Number of securities called by warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,250,000

'

'

'

'

Number of securities called by warrants associated with each disbursement borrowing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

Amount of initial draw-down under Facility Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

Net Proceeds from Initial Draw Under Facility Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,500,000

'

'

'

'

'

'

Transaction fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

Number of warrants issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

Warrants value

'

'

'

5,700,000

'

'

'

'

'

'

'

'

'

'

'

4,700,000

'

'

'

'

'

'

Warrant amount reclassified as debt discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

Litigation Settlement, Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,750,000

15,750,000

Restricted cash

'

$17,750,000

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Equal Annual Payments to Make Under Facility Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

Debt_Principal_Payments_on_Deb

Debt - Principal Payments on Debt (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
Remainder of 2014	$2,997
2015	3,000
2016	48,501
2017	6,667
2018	6,667
Thereafter	6,666
Total	74,498
Add: capital lease principal payments	1,216
Unamortized Debt Issuance And Debt Discount	-7,410
Total	68,304
Less: current portion of long-term debt	-4,189
Long-term debt, net of current portion	$64,115

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

In Millions, unless otherwise specified

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2004

Jul. 31, 2005

Dec. 31, 2007

Dec. 31, 2006

Feb. 10, 2014

31-May-08

Mar. 31, 2014

31-May-08

Mar. 31, 2014

Mar. 15, 2014

Mar. 31, 2014

Mar. 15, 2014

Mar. 15, 2014

Jan. 08, 2014

Apr. 10, 2014

Scient'x [Member]

Surgiview [Member]

Eurosurgical [Member]

Eurosurgical [Member]

Eurosurgical [Member]

Healthpoint Capital [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Beginning Fourth Quarter of 2014 [Member]

Healthpoint Capital [Member]

Subsequent Event [Member]

Scient'x [Member]

Scient'x [Member]

Healthpoint Capital [Member]

Healthpoint Capital [Member]

Orthotec LLC, Litigation Settlement [Member]

Orthotec LLC, Litigation Settlement [Member]

Scient'x [Member]

Loss Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital leases expire date

30-Jun-17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lease interest rate

'

'

'

'

'

'

'

'

6.60%

'

9.60%

'

'

'

'

'

'

Rent expense

$1

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Judgment assessed by court

'

'

'

'

30

9

'

'

'

'

'

49

'

'

31.5

'

'

Litigation Settlement, Expense

'

'

'

'

'

'

'

'

'

'

'

'

1.75

'

'

'

15.75

Business acquisition, percentage of interest acquired

'

'

33.10%

73.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency, Damages Sought, Value

'

'

'

'

'

'

47.9

39

'

70

'

'

'

'

'

'

'

Litigation settlement, quarterly installments, amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.1

'

'

Litigation settlement, contribution by entity involved, amount

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

Litigation settlement interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7.00%

'

'

Litigation settlement interest, quarterly installments, amount

'

'

'

'

'

'

'

'

'

'

'

1.1

'

'

'

'

'

Attorneys' fees paid by insurance carriers

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.25

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Annual Lease Payments (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Leases [Abstract]	'
Operating leases Remainder of 2014	$2,452
Operating leases 2015	2,724
Operating leases 2016	1,424
Operating leases 2017	247
Operating leases 2018	58
Operating leases Thereafter	2
Operating leases, Future Minimum Payments Due, Total	6,907
Capital leases Remainder of 2014	391
Capital leases 2015	461
Capital leases 2016	422
Capital leases 2017	82
Capital leases 2018	0
Capital leases Thereafter	0
Total Capital leases	1,356
Less: amount representing interest	-140
Present value of minimum lease payments	1,216
Current portion of capital leases	-442
Capital leases, less current portion	$774

Net_Loss_Per_Share_Weighted_Av

Net Loss Per Share - Weighted Average Number of Common Shares Outstanding (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator:	'	'
Net loss	($6,673)	($2,649)
Denominator:	'	'
Weighted average common shares outstanding	97,668	96,701
Weighted average unvested common shares subject to repurchase	-830	-875
Weighted average common shares outstanding—basic	96,838	95,826
Effect of dilutive securities:	'	'
Options, warrants and restricted share awards	0	0
Weighted average common shares outstanding—diluted	96,838	95,826
Net loss per common share:	'	'
Basic and diluted net loss per share	($0.07)	($0.03)

Net_Loss_Per_Share_WeightedAve

Net Loss Per Share - Weighted-Average Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities not included in diluted net loss per share	17,052	5,408
Options to purchase common stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities not included in diluted net loss per share	5,378	3,939
Unvested restricted share awards [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities not included in diluted net loss per share	830	875

Equity_Transactions_Additional

Equity Transactions - Additional Information (Details) (USD $)	3 Months Ended				0 Months Ended		3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 17, 2014	Dec. 31, 2013	Mar. 20, 2014	Mar. 17, 2014	Mar. 31, 2014	Mar. 17, 2014
					Deerfield [Member]	Deerfield [Member]	Deerfield [Member]	Maximum [Member]
								Deerfield [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'
Number of securities called by warrants	'	'	'	'	'	6,250,000	'	'
Exercise price of warrants	'	'	'	'	1.39	1.39	'	'
Number of securities called by warrants associated with each disbursement borrowing	'	'	'	'	'	'	'	10,000,000
Number of days following borrowing request to determine exercise price associated with each disbursement borrowing under facility agreement	'	'	'	'	'	'15 days	'	'
Maximum borrowing capacity	'	'	'	'	'	$50,000,000	'	'
Warrants value	'	'	5,700,000	'	4,700,000	'	'	'
Warrant amount reclassified as debt discount	'	'	'	'	2,300,000	'	'	'
Number of warrants issued	'	'	'	'	4,000,000	'	'	'
Amount of initial draw-down under Facility Agreement	'	'	'	'	20,000,000	'	'	'
Net Proceeds from Initial Draw Under Facility Agreement	'	'	'	'	19,500,000	'	'	'
Warrants issued and outstanding	'	'	'	'	'	'	10,250,000	'
Other income (expense)	383,000	-650,000	'	'	'	'	100,000	'
Common stock warrant liabilities	$10,250,000	'	'	$0	'	'	'	'
Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract]	'	'	'	'	'	'	'	'
Risk-free interest rate	1.90%	'	'	'	'	'	'	'
Dividend yield	0.00%	'	'	'	'	'	'	'
Expected volatility	74.00%	'	'	'	'	'	'	'
Expected life (years)	'6 years	'	'	'	'	'	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits increase	$0.10
Unrecognized tax benefits	$7.90

Segment_and_Geographical_Infor2

Segment and Geographical Information - Additional Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
	Location	Location
	Segment
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Number of operating segments	1	'
Number of reportable business segment	1	'
Number of geographic regions	2	2
Revenue	$49,173	$50,443
Minimum percentage of revenues	'	10.00%
Japan [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Revenue	$7,700	$6,400
Minimum percentage of revenues	10.00%	'

Segment_and_Geographical_Infor3

Segment and Geographical Information - Schedule of Revenues Attributed to Geographic Location of Customer (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Total consolidated revenues	$49,173	$50,443
Reportable Geographical Components [Member] | United States [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Total consolidated revenues	32,050	33,062
Reportable Geographical Components [Member] | International [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Total consolidated revenues	$17,123	$17,381

Segment_and_Geographical_Infor4

Segment and Geographical Information - Schedule of Long Lived Assets by Geographical Areas (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$386,282	$365,630
Reportable Geographical Components [Member] | United States [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	223,667	196,383
Reportable Geographical Components [Member] | International [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Total consolidated assets	$162,615	$169,247

Restructuring_Additional_Infor

Restructuring - Additional Information (Details) (USD $)	0 Months Ended	3 Months Ended
	Sep. 16, 2013	Mar. 31, 2014	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expected cost	$11,600,000	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Accrued Balance at December 31, 2013	'	9,170,000	'
Expensed	'	776,000	0
Paid and Other	'	-639,000	'
Accrued Balance at March 31, 2014	'	9,307,000	'
Total Costs Incurred	'	10,441,000	'
Total Expected Remaining Costs	'	1,200,000	'
Social Plan [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expected cost	'	10,000,000	'
Restructuring Reserve [Roll Forward]	'	'	'
Accrued Balance at December 31, 2013	'	9,170,000	'
Expensed	'	287,000	'
Paid and Other	'	-336,000	'
Accrued Balance at March 31, 2014	'	9,121,000	'
Total Costs Incurred	'	9,540,000	'
Total Expected Remaining Costs	'	500,000	'
Other Restructuring [Member]	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring expected cost	'	1,600,000	'
Restructuring Reserve [Roll Forward]	'	'	'
Accrued Balance at December 31, 2013	'	0	'
Expensed	'	489,000	'
Paid and Other	'	-303,000	'
Accrued Balance at March 31, 2014	'	186,000	'
Total Costs Incurred	'	901,000	'
Total Expected Remaining Costs	'	$700,000	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Healthpoint Capital [Member]	'	'
Related Party Transaction [Line Items]	'	'
Incurred expenses	$0.10	'
Payable liability	0.2	'
New York Orthotec matter [Member]	'	'
Related Party Transaction [Line Items]	'	'
Legal expenses	$0.10	$0.60